Calquence/acalabrutinib Cost, Side effects, Dosage, Uses for Mantle cell lymphoma. The FDA granted the accelerated approval of Calquence to AstraZeneca Pharmaceuticals LP. US FDA approved new drug Calquence that contains acalabrutinib for the treatment of mantle cell lymphoma in adult patients who are not responding to prior therapy. US FDA granted accelerated approval of this medicine based on results received from single arm trial.
Mantle cell lymphoma (MCL) is a kind of non-Hodgkin's lymphoma and accounts for 6% of non-Hodgkin's lymphoma. Some commonly observed symptoms of Mantle cell lymphoma are extreme weight loss, mild fever, fatigue, lymph nodes enlargement, lumps in the body, sweating at night time. Enlarged spleen is another common finding during ultrasound in case of Mantle cell lymphoma. You health care provider may ask you for biopsy for further analysis of disease.
Exact underlying cause of Mantle cell lymphoma is not fully understood but many scientist assume that combination of factors like genetic predisposition, environmental factors, old age, alcoholism and sedentary lifestyle are important in the pathogenesis of Mantle cell lymphoma. Life expectancy and survival rate of mantle cell lymphoma heavily depends upon
Calquence/acalabrutinib is based on novel drug delivery system. This drug belongs to a class known as Bruton's tyrosine kinase (BTK) inhibitor. It is more potent in efficacy and has less side effects as compared other agents that belongs to bruton's tyrosine kinase (BTK) inhibitor class like ibrutinib. Main mechanism by which it restricts the proliferation of cancer cells is by blocking an enzyme needed by the cancer to multiply and spread.
According to health authorities following side effects were observed during clinical trails of this drug.
US FDA approved this drug for the treatment of Mantle cell lymphoma in adult patients who are not responding to conventional therapy. On the basis of initial data received from clinical trials this drug should be avoided in pregnancy and breastfeeding.
Recommended dose is 100 mg orally approximately every twelve hours. Swallow whole capsule with water and with or without food. Do not chew or break the capsule because it may cause drug loss or reduce the efficacy of drug. Dose titration must be consider in case of toxicity or other unexpected side effect that can not be tolerated.
Mantle cell lymphoma (MCL) is a kind of non-Hodgkin's lymphoma and accounts for 6% of non-Hodgkin's lymphoma. Some commonly observed symptoms of Mantle cell lymphoma are extreme weight loss, mild fever, fatigue, lymph nodes enlargement, lumps in the body, sweating at night time. Enlarged spleen is another common finding during ultrasound in case of Mantle cell lymphoma. You health care provider may ask you for biopsy for further analysis of disease.
Exact underlying cause of Mantle cell lymphoma is not fully understood but many scientist assume that combination of factors like genetic predisposition, environmental factors, old age, alcoholism and sedentary lifestyle are important in the pathogenesis of Mantle cell lymphoma. Life expectancy and survival rate of mantle cell lymphoma heavily depends upon
Calquence/acalabrutinib is based on novel drug delivery system. This drug belongs to a class known as Bruton's tyrosine kinase (BTK) inhibitor. It is more potent in efficacy and has less side effects as compared other agents that belongs to bruton's tyrosine kinase (BTK) inhibitor class like ibrutinib. Main mechanism by which it restricts the proliferation of cancer cells is by blocking an enzyme needed by the cancer to multiply and spread.
Calquence/acalabrutinib Side effects
According to health authorities following side effects were observed during clinical trails of this drug.
- Generalized weakness
- Fatigue
- Headche
- Swelling
- Brusing
- Low red blood cells count
- Low platelets count
- Mild fever
- Diarrhea
- Skin irritation
Calquence/acalabrutinib Uses/Prescribing Information
US FDA approved this drug for the treatment of Mantle cell lymphoma in adult patients who are not responding to conventional therapy. On the basis of initial data received from clinical trials this drug should be avoided in pregnancy and breastfeeding.
Calquence/acalabrutinib Dosage
Recommended dose is 100 mg orally approximately every twelve hours. Swallow whole capsule with water and with or without food. Do not chew or break the capsule because it may cause drug loss or reduce the efficacy of drug. Dose titration must be consider in case of toxicity or other unexpected side effect that can not be tolerated.
0 Comments
For comments please reply here.......